NCT05576922
Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 12 words
- Trial completed
- Secondary endpoints: details revised at 2 of 6 entries
- Study Identification, Study Status, Study Designv6
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Primary completion date: Oct 20, 2024 to Oct 20, 2025
- Study completion date: Oct 21, 2024 to Oct 21, 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jan 10, 2023 to Jan 4, 2023
- Notable Start date: Oct 20, 2022 to Jan 10, 2023v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Soft tissue dehiscence reduction
Timeframe: 6 and 12 months
Secondary (6)
Complete peri-implant soft tissue dehiscence (PSTD) coverage
mean peri-implant soft tissue dehiscence (PSTD) coverage
Mucosal thickness changes
3D Volumetric changes
Post-operative pain
Show 1 moreShow less
Professional esthetic assessment
Arms and interventions
Connective tissue graftActive comparator
Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized
Collagen matrix + rhPDGF-BBExperimental
Xenogeneic cross-linked collagen matrix + recombinant human platelet-derived growth factor-BB
Other: Prosthetic-surgical approach + autogenous graft, Prosthetic-surgical approach + graft substitute
Sites
1 site in 1 country
- Harvard School of Dental MedicineBoston, Massachusetts, United States